The reduction in DLC2 expression in triple-negative breast cancer was greater than that of DLC1 or DLC3. In colon cancer, where DLC1 expression had not predominated in the normal tissue, there was a 2-fold reduction for all three DLCs genes (Figure 2E). This evidence concerns the gene STARD13 and malignant colon neoplasm.